Who
Bonnie L. Bassler
Director
Company insider
Files Form 4 as: Director, Royalty Pharma; Director, Regeneron Pharmaceuticals; Director, Cidara Therapeutics; Director, Kaleido Biosciences.
In numbers
- Trades disclosed
- 163
- Buys
- 0
- Sells
- 24
- Bought
- $0
- Sold
- $23.5M
- Companies
- 4
- Companies where not an officer
- 4
- First trade
- 9 Sep 2016
- Last trade
- 30 Sep 2026
- Last filed
- 30 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 30 Sep 2026filed 30 Sep 2026 | RPRX Royalty PharmaPharmaceuticals | SEC FORM 4 Code A | $37K642 at $58.41 | filing |
| 30 Sep 2026filed 30 Sep 2026 | RPRX Royalty PharmaPharmaceuticals | SEC FORM 4 Code A | $37K642 at $58.41 | filing |
| 30 Jun 2026filed 30 Jun 2026 | RPRX Royalty PharmaPharmaceuticals | SEC FORM 4 Code A | $37K689 at $54.40 | filing |
| 30 Jun 2026filed 30 Jun 2026 | RPRX Royalty PharmaPharmaceuticals | SEC FORM 4 Code A | $37K689 at $54.40 | filing |
| 5 Jun 2026filed 8 Jun 2026 | RPRX Royalty PharmaPharmaceuticals | SEC FORM 4 Code A | —4,545 at $0.00 | filing |
| 5 Jun 2026filed 8 Jun 2026 | RPRX Royalty PharmaPharmaceuticals | SEC FORM 4 Code A | —4,545 at $0.00 | filing |
| 31 Mar 2026filed 31 Mar 2026 | RPRX Royalty PharmaPharmaceuticals | SEC FORM 4 Code A | $37K815 at $45.98 | filing |
| 31 Mar 2026filed 31 Mar 2026 | RPRX Royalty PharmaPharmaceuticals | SEC FORM 4 Code A | $37K815 at $45.98 | filing |
| 7 Jan 2026filed 8 Jan 2026 | REGN Regeneron PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $561K1,500 at $374.12 | filing |
| 7 Jan 2026filed 8 Jan 2026 | REGN Regeneron PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $1.2M1,500 at $800.00 | filing |
| 7 Jan 2026filed 8 Jan 2026 | REGN Regeneron Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —1,500 at $0.00 | filing |
| 7 Jan 2026filed 8 Jan 2026 | REGN Regeneron Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —1,500 at $0.00 | filing |
| 7 Jan 2026filed 8 Jan 2026 | REGN Regeneron PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $561K1,500 at $374.12 | filing |
| 7 Jan 2026filed 8 Jan 2026 | REGN Regeneron PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $1.2M1,500 at $800.00 | filing |
| 7 Jan 2026filed 7 Jan 2026 | Cidara TherapeuticsBiotechnology | SEC FORM 4 Code D | $3,32315 at $221.50 | filing |
| 7 Jan 2026filed 7 Jan 2026 | Cidara Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —1,750 | filing |
| 7 Jan 2026filed 7 Jan 2026 | Cidara Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —875 | filing |
| 7 Jan 2026filed 7 Jan 2026 | Cidara Therapeuticsoption or derivative | SEC FORM 4 Code D | —1,750 | filing |
| 7 Jan 2026filed 7 Jan 2026 | Cidara Therapeuticsoption or derivative | SEC FORM 4 Code D | —875 | filing |
| 7 Jan 2026filed 7 Jan 2026 | Cidara Therapeuticsoption or derivative | SEC FORM 4 Code D | —1,400 | filing |
News
1,598 Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Perpetual LtdREGN · dailypolitical.com · 15 Oct 2026Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Price Up 3.6% – Here's What HappenedREGN · dailypolitical.com · 14 Oct 2026Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Raised to $780.00REGN · dailypolitical.com · 10 Oct 2026
0 headlines in the last 90 days name Bonnie L. Bassler; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.